Author pages are created from data sourced from our academic publisher partnerships and public sources.
Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ.
IMPORTANCE Women with ductal carcinoma in situ (DCIS), or stage 0 breast cancer, often experience a second primary breast cancer (DCIS or invasive), and some ultimately die of breast cancer. … Expand
Low-grade serous ovarian cancer: A review.
- Anis Kaldawy, Y. Segev, O. Lavie, R. Auslender, V. Sopik, S. Narod
- Gynecologic oncology
- 1 November 2016
Epithelial ovarian cancers can be divided into the more common, aggressive type II cancers and the less common, slow-growing type I cancers. Under this model, serous ovarian carcinomas can be… Expand
Why have ovarian cancer mortality rates declined? Part I. Incidence.
The age-adjusted mortality rate from ovarian cancer in the United States has declined over the past several decades. The decline in mortality might be the consequence of a reduced number of cases… Expand
Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis.
BACKGROUND Mutations in PALB2 predispose to breast cancer, but the effect on prognosis of carrying a PALB2 mutation has not been ascertained. We aimed to estimate the odds ratio for breast cancer in… Expand
BRCA1 and BRCA2 mutations and the risk for colorectal cancer
Women who carry a BRCA1 or BRCA2 mutation are at high risk of breast and ovarian cancer, and may be at moderately increased risk of other cancer types. This review examines studies to date that have… Expand
Genetic testing for RAD51C mutations: in the clinic and community
Much of the observed familial clustering of breast and ovarian cancer cannot be explained by mutations in BRCA1 and BRCA2. Several other cancer susceptibility genes have been identified, but their… Expand
Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer
- J. Lerner-Ellis, S. Khalouei, V. Sopik, S. Narod
- Expert review of anticancer therapy
- 2 November 2015
Multigene panel tests are being increasingly used for the genetic assessment of women with an apparent predisposition to breast cancer. Here, we review all studies reporting results from individuals… Expand
Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland
A number of genes other than BRCA1 and BRCA2 have been associated with breast cancer predisposition, and extended genetic testing panels have been proposed. It is of interest to establish the full… Expand
Ten-year survival in women with primary stage IV breast cancer
PurposeTo evaluate breast cancer-specific survival at 10 years in patients who present with primary stage IV breast cancer, and to determine whether survival varies with age of diagnosis.MethodsWe… Expand
Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ
BackgroundDuctal carcinoma in situ (DCIS) is a neoplastic proliferation of epithelial cells which is confined within the basement membrane of the mammary ductal–lobular system. It is of interest to… Expand